Scorpius Holdings has been accepted into the Biopharmaceutical Manufacturing Preparedness Consortium, a part of the National Biopharmaceutical Manufacturing Partnership. The BioMap-Consortium has a $20 billion funding ceiling, through which it provides growth funding, as well as streamlined access to servicing government-funded manufacturing programs. The BioMaP-Consortium supports the Biomedical Advanced Research and Development Authority and is comprised of industry partners across the drug and vaccine manufacturing supply chain, including manufacturers of raw materials and consumables, developers of innovative manufacturing technologies, and suppliers of fill finish services. This consortium seeks to expand the industrial and manufacturing base for medical countermeasures to include the requisite capabilities, flexibilities, and strategies to secure needed medical supplies to meet the nation’s public health preparedness and response requirements.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SCPX:
- Scorpius Holdings Accepted as a Member of the US Government’s BioMaP-Consortium
- Scorpius Holdings, Inc. Announces Closing of Public Offering
- Scorpius Holdings 10M share Spot Secondary priced at 15c
- Scorpius Holdings, Inc. Announces Pricing of Public Offering
- Scorpius Holdings files to sell common stock, no amount given